Articoli originali Open access

Sindrome da Ipertermia Maligna: una revisione bibliografica

Autori

Pubblicato
19 gennaio 2018
Sezione
Articoli originali
DOI
10.4081/scenario.2014.102
Pagine
5-18

Abstract

Introduzione: la sindrome da Ipertermia Maligna o Malignant Hyperthermia (MH) è una rara e gravissima complicanza dell’anestesia generale, che si presenta in soggetti geneticamente predisposti in seguito all’esposizione a fattori scatenanti (gas alogenati e succinilcolina cloruro). È un’emergenza medica che non presenta un quadro clinico di chiara identificazione. Tutti gli infermieri, specie quelli d’anestesia, dovrebbero essere formati per essere pronti a gestirla.

Agenzie di supporto

Riferimenti bibliografici

  1. DENbOROugH MA, LOvELL RRH. Anaesthetic deaths in a family. Lancet 2(45), 1960.
  2. TARuSCIO D. Le malattie rare. In: Malattie rare in età pediatrica. Istituto Superiore Sanità . [Online] 2014. Available from www.iss.it/cnmr cited
  3. March 16.
  4. ROSEMbERg H, DAvIS M, JAMES D, POLLOCk N, STOwELL K. Malignant Hyperthermia, Orphanet J Rare Dis. 2007; Apr; 24; 2:21.
  5. ACCORSI A, bRANCADORO v, CARSANA A, COZZOLINO S, DI MARTINO A, FORTuNATO G et al. [Raccomandazioni in tema di Ipertermia Maligna. Gruppo di stu-
  6. dio SIAARTI per la sicurezza in Anestesia e Terapia Intensiva]. Minerva Anest 1997 Sep;63(9):279-85.
  7. LI g, bRADy JE, ROSENbERg H, SuN LS. Excess comorbidities associated with malignant hyperthermia diagnosis in pediatric hospital discharge re-
  8. cords. Paediatr Anaesth. 2011 Sept; 21(9): 958-63.
  9. DuNN D. Malignant hyperthermia. AORN J. 1997 Apr; 65(4): 728-31.
  10. gROuP EMH. A protocol for the investigation of malignant hyperpirexia (MH). Br J Anaesth. 2010; 105(4): 417-20.
  11. ANDERSON-POMPA k, FOSTER A, PARkER L, wILkS L, CHEEk D, MILL T, et al. Genetics and susceptibility to malignant hyperthermia. Crit Care Nurse. 2008
  12. Dec; 6(28): 32-6.
  13. JAMES D, POLLOCk N, ROSEMbERg H, DAvIS M. Malignant hyperthermia. Orphanet Journal of Rare Diseases. 2007; 21(2). HOPkINS P. Malignant hyper- thermia: pharmacology of triggering. British Journal of Anaesthesia. 2011 May 30; 107(1): 48-56.
  14. LITMAN R, ROSEMbERg H. Malignant hyperthermia: update on susceptibility testing. JAMA. 2005 Jun 15; 293(23): 2918-24.
  15. LARACH bg, bRANDOM bw, ALLEN gC, gRONERT gA, LEHAM EB. Cardiac arrests and deaths associated with malignant hyperthermia in North America from 1987 to 2006: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the Uni-
  16. ted States. Anesthesiology. 2008 Apr; 108(4): 603-11.
  17. kIM T, NEMERguT M. Preparation of modern anesthesia workstations for malignant hyperthermia-susceptible patients: a review of past and pre-
  18. sent practice. Anesthesiology. 2011 Jan; 114(1): 205-12.
  19. CHANg C, SCHER R. Malignantr hyperthermia and the otolaryngologist. Ear Nose Throat J. 2003 Jun; 82(6): 433-6.
  20. NATHAN M. Malignant hyperthermia: perioperative considerations. Semin Perioper Nurs. 1993 Jan; 2(1): 38-44.
  21. MIRANDA A, DONOvAN L, SCHuSTER L, gERbER D. Malignant hyperthermia. Am J Crit Care. 1997 Sep; 6(5): 368-74.
  22. wOLCOTT k, MCDONNELL A. Malignant hyperthermia: nursing implications. Crit Care Nurse. 1990 Mar; 10(3): 78-85.
  23. MARTIN S, vANE E. Malignant hyperthermia: a case study. Semin Perioper Nurs. 2000 Jan; 9(1): 27-36.
  24. ROSEMbERg H, RuEFFERT H. Clinical utility gene card for malignant hyperthermia. European Journal of Human Genetics. 2011 Jan 19 doi:
  25. 1038/ejhg.2010.248; [published online 19 January 2011].
  26. wAPPLER F. Anesthesia for patients with a history of malignant hyperthermia. Curr Opin Anaesthesiol. 2010 Jun; 23(3): 417-22.
  27. wAPPLER F. Preparation of modern anesthesia workstations for malignant hyperthermia-suceptible patients: when are they really clean? Anes-
  28. thesiology. 2011 Aug; 2(115): 434-5.
  29. kugLER y, RuSSELL w. Speeding dantrolene preparation for treating malignant hyperthermia. Anaesth Intensive Care. 2011 Jan; 39(1): 84-8.
  30. bRANDOM b, LARACH M, CHEN M, yOuNg M. Complications associated with the administration of dantrolene 1987 to 2006: a report from the North
  31. American Malignant Hyperthermia Registry of the United States. Anesth Analg. 2011 May; 5(112): 1115-23.
  32. PODRANSkI T, bOuILLON T, SCHuMACHER P, TAguCHI A, SESSLER D, kuRZ A. Compartmental pharmacokinetics of dantrolene in adults: do malignant hyper-
  33. thermia association dosing guidelines work? Anesth Analg. 2005 Dec; 101(6): 1695-9.
  34. INADA H, JINNO S, kOHASE H, FukAyAMA H, uMINO M. Postoperative hyperthermia of unknown origin treated with dantrolene sodium. Anesth Prog.
  35. ; 52(1): 21-3.
  36. bAkER k, LANDRISCINA D, kARTCHNER H, MIRkES D. The Icarus effect: the in uence of diluent warming on dantrolene sodium mixing time. AANA J. 2007
  37. Apr; 75(2): 101-6.
  38. HALASZyNSkI T, JuDA R, SILvERMAN D. Optimizing postoperative outcomes with ef cient preoperative assessment and management. Crit Care Med.
  39. Apr; 32(4): 76-86.
  40. bLOCk FJ. Malignant hyperthermia and charcoal absorbent: too hot to handle. Anesth Analg. 2011 Jun; 6(112): 1270-1.
  41. HOTCHkISSM,MENDOZAS.Updatefornurseanesthetists.Part6.Fullbodypatientsimulationtechnology:gainingexperienceusingamalignant
  42. hyperthermia model. AANA J. 2001 Feb; 69(1): 59-65.

Metriche

Citazioni e attenzione online da Dimensions, Altmetric e PlumX.

PlumX Metrics

Licenza

Aniarti ha scelto di applicare la Licenza Creative Commons Attribuzione Non Commerciale 4.0 Internazionale (CC BY-NC 4.0) a tutti i manoscritti da pubblicare.